The BSH Guidelines Official Podcast – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

The BSH Guidelines Official Podcast

British Society for Haematology

Health & Fitness

Science

Education

Frequency: 1 episode/26d. Total Eps: 84

Written by expert consultants and clinical scientists currently practising in the UK, the BSH Guidelines provide up-to-date evidence-based guidance on the diagnosis and treatment of haematological diseases. Self accreditation Listen to two podcasts and earn one CPD point via self-accreditation Join our Guidelines Newsletter to be notified when new guidelines/good practice papers are published by going into your members account under MyBSH. Non members can email bshguidelines@b-s-h.org.uk to sign up for updates.

Read moreCollapse

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇬🇧 Great Britain - medicine
09/08/2026
#85
🇬🇧 Great Britain - medicine
08/08/2026
#49
🇬🇧 Great Britain - medicine
07/08/2026
#67
🇬🇧 Great Britain - medicine
28/07/2026
#65

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 37%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

The assessment and management of bleeding risk prior to invasive procedures

Episode 55

Monday, July 22, 2024 • Duration 47:51

This guidance update from the BSH is focussed primarily on non-surgical invasive procedures, simply termed ‘procedures’ in this document, with the primary objective of giving pragmatic advice where evidence is limited. This guidance also aims to reduce unnecessary laboratory testing, inappropriate use of blood products and unnecessary delays in therapeutic procedures.1 It should be read in conjunction with the Interventional Radiology (IR) procedure bleeding risk guidance produced by the British Society of Interventional Radiology (BSIR) and the BSH.2 Recommendations are predominantly based on evidence from adult patients and therefore may not be applicable to neonates or very young children.

Read moreCollapse

The management of myelofibrosis: A British Society for Haematology Guideline

Episode 54

Monday, July 22, 2024 • Duration 26:11

Podcast by Dr Donal P. McLornan on The management of myelofibrosis.

Guideline on the investigation and management of acute transfusion reactions

Episode 45

Wednesday, July 12, 2023 • Duration 19:06

Haematological management of major haemorrhage

Episode 44

Wednesday, June 7, 2023 • Duration 21:07

Haematological management of major haemorrhage: A podcast recording of a conversation between Prof Simon Stanworth and Dr Heidi Doughty.

Anticoagulant management of pregnant individuals with mechanical heart valves

Episode 43

Friday, May 26, 2023 • Duration 16:57

A BSH Guideline on the Anticoagulant management of pregnant individuals with mechanical heart valves presented by Dr Will Lester.

Management of secondary central nervous system lymphoma: A British Society for Haematology Good Practice Paper

Episode 41

Thursday, December 8, 2022 • Duration 17:07

Secondary central nervous system (CNS) lymphoma (SCNSL) refers to lymphoma that has spread to the CNS concurrently with, or following treatment for, systemic lymphoma. There are three clinically distinct scenarios:

Synchronous CNS and systemic lymphoma at initial presentation (treatment-naïve; TN-SCNSL),
CNS relapse without recurrent systemic lymphoma (relapsed isolated CNS lymphoma; RI-SCNSL).
Relapsed concomitant systemic and CNS disease following treatment for systemic lymphoma (RC-SCNSL).

CNS lymphoma (CNSL) is associated with inferior outcomes, which may be attributed to several factors: poor CNS penetrance of chemotherapeutics, including RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone),1 impaired neurocognitive function and patient performance status (PS) contributing to increased treatment toxicity,2, 3 and recurrent genetic aberrations conferring treatment resistance.4-6 The rarity and heterogeneity of SCNSL also limits the evidence base for treatment recommendations, with poor outcomes potentially attributable at least in part to lack of optimised treatment protocols.

This good practice paper focuses on diffuse large B-cell lymphoma (DLBCL), the most common SCNSL subtype. It covers diagnostic and therapeutic aspects of care for the three SCNSL scenarios and multiply relapsed SCNSL. Treatment recommendations are framed by patient fitness and treatment intent.

Read moreCollapse

Guidelines for thrombophilia testing

Episode 40

Monday, November 28, 2022 • Duration 24:41

This guideline updates and widens the scope of the previous British Society for Haematology (BSH) Clinical guidelines for testing for heritable thrombophilia1 to include both heritable and acquired thrombophilia.

The term thrombophilia is generally used to describe hereditary and/or acquired conditions associated with an increased predisposition to thrombosis. Heritable thrombophilia refers to genetic disorders of specific haemostatic proteins. These guidelines focus only on the factors that are identified from laboratory testing and therefore exclude disorders such as cancer, inflammatory conditions and obesity that are associated with thrombosis through multiple mechanisms.

Read moreCollapse

Good Practice Paper for management of older patients with frailty and acute myeloid leukaemia

Episode 39

Friday, August 26, 2022 • Duration 14:47

Audio commentary from Dr Mike Dennis on the good practice paper - management of older patients with frailty and acute myeloid leukaemia.

Guideline for the first-line management of Classical Hodgkin Lymphoma

Episode 38

Tuesday, July 19, 2022 • Duration 29:41

Audio commentary by Dr George Follows.

Guideline for the treatment of chronic lymphocytic leukaemia

Episode 36

Monday, June 13, 2022 • Duration 30:09

Dr Nilima Parry Jones and Dr Renata Walewska present a podcast on the Guideline for the treatment of chronic lymphocytic leukaemia

Both Dr Parry Jones and Dr Walewska discuss the guideline in three main parts:

1) Choice of treatment for CLL in front line and relapsed settings

2) Impact to immune dysregulation in respect of anti-microbial prophylaxis and vaccination

3) Challenges of the Covid pandemic, the evolving evidence on vaccine response, treatment of patients with Covid and antiviral and monoclonal antibodies

Dr Nilima Parry-Jones is a Consultant Haematologist at the Aneurin Bevan Local Health, Wales and an executive member of the UK CLL Forum. She is the Chair of the BSH Haematology Oncology Task Force.

Dr Renata Walewska is a Consultant Haematologist at the Royal Bournemouth Hospital and Chair of the UK CLL Forum.

Read moreCollapse

The BSH Guidelines Official Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

The BSH Guidelines Official Podcast – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Shared links between episodes and podcasts

Other65

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other65